ULURU INC (ULUR) - Ein Stern ist geboren - 500 Beiträge pro Seite

[Quipu]

http://www.uluruinc.com/

http://finance.yahoo.com/q?s=ULUR.OB

http://quotes.freerealtime.com/dl/frt/N?SA=quotes|Profile&IM…

Zwei Tage alt ist das Baby, das gleich jugendlich zur Welt kam.

Vater: OXFORD VENTURES, Mutter: ACCESS PHARMACEUTICALS INC

Aus diesen Thread können Sie sich erst einmal Informationen holen:
Thread: OXFV - das Baby Uluru wird schnell wachsen!!
Thread: +32%. Oxford Ventures unmittelbar vor erneutem Boom?

Alles deutet darauf hin, dass es ein gesundes Kind ist, dass es sehr schnell wachsen wird.

[calibra21]

Antwort auf Beitrag Nr.: 21.126.615 von Quipu am 07.04.06 20:36:00

Richtig! Bin seit einer Ewigkeit dabei und bin nach wie vor von der Story fest überzeugt!

[Quipu]

Die Geburtsurkunde:

Oxford Ventures Announces Completion of Merger With ULURU
Wednesday April 5, 8:00 am ET - Name Change to ULURU Inc.
- Symbol Change on the OTC Bulletin Board: ULUR
- Implementation of Reverse Stock Split


DALLAS, April 5 /PRNewswire-FirstCall/ -- Oxford Ventures, Inc. (OTC Bulletin Board: OXFV - News; "OXFORD") today announced that its merger with ULURU, Inc. ("ULURU") has been completed. Under the terms of the merger agreement, ULURU has been merged into a subsidiary of Oxford, with Oxford being the surviving legal entity. Oxford has acquired all of the outstanding shares of ULURU in exchange for unregistered common stock of Oxford.
Oxford's name has been changed to ULURU Inc. and the new company headquarters are located at 4452 Beltway Drive, Addison, Texas, 75001.

Mr. Kerry P. Gray will be President and C.E.O. of ULURU. Additionally, Mr. Gray will serve on the Board of Directors along with:


Mr. William W. Crouse, Chairman
Mr. Jeffery B. Davis
Dr. David E. Reese

Effective April 5, 2006 the trading symbol on the OTC Bulletin Board will change from OXFV to ULUR. Additionally, the company has implemented a 1-for-400 reverse stock split. The reverse stock split will take effect and the shares will begin trading on a post-split basis at the opening of business on Wednesday, April 5, 2006.

With the completion of the merger and the reverse stock split the company will have approximately 13 million common shares outstanding. Shareholders will be notified by Continental Stock Transfer & Trust Company, ULURU's stock transfer agent, regarding the process for receiving new share certificates.

ULURU's business plan is to establish a market leadership position in the development of wound management, plastic surgery and oral care products utilizing innovative drug delivery solutions to improve clinical outcomes for patients and provide an economic benefit to healthcare providers. The company intends to establish a sales and marketing organization to market our product developments to the wound management and plastic surgery markets and to form strategic partnerships to market our range of oral products and other product developments that require a large sales organization. Acquiring and licensing products for wound management and plastic surgery is an integral component of our strategy of rapidly building a sales and marketing organization.

Commenting on the recent developments, Kerry P. Gray, President and C.E.O. of ULURU, stated, "With the completion of the merger and the appointment of a highly qualified Board of Directors, I look forward with excitement to building a leading company in the wound management, plastic surgery and oral care markets. We are very pleased with our progress in developing products from our technology platforms. Over the upcoming 12 months we expect three additional products to be marketed."

Mr. Gray continued, "The reverse split brings the number of shares outstanding and the share price more in line with companies of our size and stage of development. This is the first step to achieve our ultimate objective of applying for a listing on NASDAQ or an exchange."

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.

[Quipu]

Antwort auf Beitrag Nr.: 21.126.651 von calibra21 am 07.04.06 20:39:08

Hallo calibra21, endlich ist es vollbracht.

Jetzt können wir uns zurück lehnen. Denn es ist kein Zockerwert.

[Quipu]

Handel in Berlin leider noch nicht möglich. Auch eine Umschreibung
der Teile von den Banken ist noch nicht erfolgt.

[Quipu]

Market Cap(Th.) 1,950 MIO
Common Shares Outst. 1,000 MIO

[KingKong2]

Antwort auf Beitrag Nr.: 21.126.813 von Quipu am 07.04.06 20:54:43

Von Papa Oxford hat das Kleine zweifellos das geschäftliche Talent geerbt, von Mama ACCESS hat es wertvolle Patente in die Wiege gelegt bekommen

[Andreito]

jetzt heisst es abwarten!!!

[olibaer2006]

Hallo zusammen,

habe Eure gesamte Leidensgeschichte mit Höhen und Tiefen bei diesem Wert verfolgt und nachgelesen.
Lohnt ein Einstieg hier noch oder hätte man vorher einsteigen sollen.

Für einen Tipp bin ich dankbar.

Grüße ins Board!

[Andreito]

ich denke hier lohnt sich noch ein einstieg, die sache faengt doch gerade ersteinmal an!!!!

[Suum_Quique]

und was machen die eigentlich genau?

und wieso sollen die jetzt steigen, und weshalb soll ich nun ivestieren?

Fragen über Fragen ...

[Andreito]

schau dir den alten oxfv thread an da ist alles beschrieben und erklaert

[Andreito]

hier ein kleiner auszug aus einen aelteren thread


-------------------------------------------------------------------



Gestern wurde vermeldet, daß Oxford Ventures Fusionspartner Uluru eine Wundgel für Brandwunden entwickeln und die US Army damit ausstatten soll.


Nach erfolgreicher Entwicklung könnte somit OXFV als alleiniger Ausrüster für Wundsalben der US Army auftreten!

Die ersten Kontrakte dürften somit nicht lange auf sich warten lassen und richtig Geld in die Kassen von OXFV spülen!


------------------------------------------------------------------

[PizPalue]

Ich hoffe doch, das es hier positiv weitergeht!
Kurs liegt z.Zt. etwa auf dem Niveau vor dem Split!

[Andreito]

bis jetzt sieht doch alles ok aus, es fehlen nur noch die news!

wurd bei einen das depot schon umgestellt? habe immer noch oxford im depot.

[Andreito]

gibts hier was neues????

[Andreito]

ULURU HOMEPAGE AUF DEUTSCH UEBERSETZT DURCH GOOGLE

http://translate.google.com/translate?u=http%3A%2F%2Fwww.ulu…

jetzt fehlen nur noch die richtigen news!!!

[Quipu]

Der Hammer bei Uluru ist, dass ein fertiges Produkt da ist und weitere
aus der Pipeline purzeln in 2006 und dass die Vermarktungsstrukturen
vorhanden sind.

Das größte Problem aller kleinen Biotec-Firmen hat Uluru nicht!!

Und darüber hinaus den Deal mit der Regierung!!
Die Regierung finanziert die Entwicklung.
Genial!!!!

Wenn zu allem die Wundsalbe noch fertig ist, dann steht
auch die Nadaq vor der Tür und und und..

Ich denke, das einzige, was den Kurs niedrig hält ist die
Angst vor Verwässerung durch Aktienausgaben, oder das Shorten.
Der Erfolg ist vorprogrammiert.

[Andreito]

erfolg ist vorprogrammier....

das kann sein...

hauptsache der kurs wird nicht verwaessert, da muss ich dir recht geben, haben die denn was von verwaesserung erweaehnt? oder besser gesagt von weiteren akien ausgabe???

[Andreito]

hat schon einer uluru im depot oder noch die alten oxford shares???

[pedro_III]

Die Banken sind auf die Lieferung durch die Lagerstelle angewiesen.
Dies kann einige Tage dauern.
Sollte uns aber auch nicht weiter stören

[Andreito]

Antwort auf Beitrag Nr.: 21.151.623 von pedro_III am 10.04.06 21:09:46

solange er kurs auswaerts ginge, wuerde es mich nicht stoeren!

[Quipu]

Antwort auf Beitrag Nr.: 21.150.312 von Andreito am 10.04.06 19:57:09

Weiß ich nicht.

Bei mir sind 500 Stück übrig geblieben.

[KingKong2]

Meine Uluru sind jetzt eingebucht, sogar mit Nachkommastellen

Aktueller Kurswert: n.V.

[Andreito]

das selbe steht auch bei mir!

ob wir heute an die 2 dollar marke gelangen???

[KingKong2]

Wäre interessant zu wissen, ob Uluru ein Listing in Berlin oder FfM plant und in welchem Zeitrahmen...

-----------------------------------------------------------
For more information about ULURU Inc., please contact:


Kerry P. Gray
President & CEO
ULURU Inc.
4452 Beltway Drive
Addison, TX 75001

Tel: [phone]
Fax: [phone]


Business Development:
W. Eric Bowditch
Vice President, Business Development
ULURU Inc.
4452 Beltway Drive
Addison, TX 75001

Tel: [phone]
Fax: [phone]
Email: [e-mail]

-----------------------------------------------------------

[PizPalue]

Hallo? Stellen wir nicht ein ungesundes Abbröckeln des Kurses fest?
2,20. 1,95, 1,80?
Oh, oh!

[Andreito]

das sind die selben schwankungen die wir vor dem split hatten! da ist der kurs auch zwischen 0,0035 und 0,005 gependelt.

[pedro_III]

Was wir jetzt brauchen sind News, News und nochmal News. Eigentlich sollte endlich positiver Newsflow einsetzen. Die Chance auf Erhöhung der eigenen Bekanntheit sollte doch jetzt einsetzen, wo das Baby noch klein ist, oder?

[Andreito]

eigentlich schon, vielleicht sollten wir mal ein mail an uluru schicken! wer hat gute englisch kentnisse????

[pedro_III]

Ich habe eine Mail abgeschickt mit einigen Fragen bezüglich der kurz- bis mittelfristigen Planung einschließlich der Frage, ob die Ausgabe neuer Aktien geplant ist.
Die Antworten stelle ich ein.

[Andreito]

Antwort auf Beitrag Nr.: 21.164.320 von pedro_III am 11.04.06 18:33:14

super gemacht! mal sehen wie lange es dauert bis sie dir antworten werden.

[SlayGrosswildjaeger]

Antwort auf Beitrag Nr.: 21.164.464 von Andreito am 11.04.06 18:41:40

Ich bin auch bei ULURU mit von der Partie!!!

...war ja schon ne ganze Weile in Oxford investiert!

..bin auch gespannt auf die Antwort!

[Andreito]

weis schon einer was neues???

[Andreito]

habe soebend ein mail an uluru geschrieben sobald ich eine antwort bekomme stelle ich sie hier rein.

meine fragen:

ke,auftraege,zukunftsausichten,wann news kommen werden

[PizPalue]

Antwort auf Beitrag Nr.: 21.184.959 von Andreito am 13.04.06 00:19:09

Antwort:
Es ist alles bestens!
"Die Zukunftsaussichten sind hervorragend!
News werden von uns sofort veröffentlich, wenn es so weit ist.
Vielleicht noch das ein oder andere Sätzchen drumherum!"
Ich überlege in der Tat, meine Shares jetzt zu verkaufen. Ein bisschen Gewinn ist noch drin.

[Andreito]

warte doch ersteinmal ab bis die naechsten news kommen.

[Andreito]

ist ganz schoen ruhig geworden, ich dachte nach dem spit und der firmenumnennung wuerde hier mehr los sein

[Andreito]

im "quotebook" stehen nur noch 2 drin, HDSN und NITE

bid 2 x 0,75

ask 1 x 2
1 x 10,05

[pedro_III]

Ziemlich schlappes Bild.
Keine Antwort auf meine Mail. Sowas hasse ich wie die Pest, man gibt sich Mühe und es kommt........nichts .

Macht zunächst keinen guten Eindruck.

Jemand andere Erkenntnisse??

[Andreito]

habe auch noch keine antwort auf meine mail bekommen und das ist schon 1 woche her

[Andreito]

wenigstens haelt sich der kurs gut...

pendeln zwischen 1.75 und 2 dollar, so wie vor dem split.

[Andreito]

noch einer da??? wo sind denn all die leute die vor dem split noch hier waren???

habe jednfalls keine antwort auf meine mail bekommen.

[Andreito]

weis einer wieso es verpaetungen mit den zahlen gibt??? haben heute ein "e" verpasst bekommen!

[Andreito]

finde heute keinen kurs bei uluru, wird nicht gehandelt oder was ist da los???

[Andreito]

gibts was neues??? also auf mails antworten die wohl nich

[Andreito]

NEWS!!!! sind aber von 4.5.


ULURU Inc. Announces Strategic Joint Development Agreement With BioProgress plc

DALLAS, May 4, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
ULURU Inc. (OTC Bulletin Board: ULURE) ("ULURU") today announced that it has signed a joint strategic development agreement with the specialty pharmaceutical and healthcare company, BioProgress plc (Nasdaq: BPRG). The companies will initially work together to develop an anti-emetic product for the relief of nausea, using a combination of BioProgress' film technology and ULURU's Oradisc(TM) drug delivery technology. This relationship will then go on to develop further therapeutic products.

ULURU is focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery. ULURU's OraDisc(TM) technology is an innovative erodible film technology that sticks to mucous membranes that allows sustained release of actives into the systemic circulation over a period of several hours.

The new products are expected to resemble BioProgress' in-the-mouth range of films strips, which dissolve instantly, releasing the embedded active ingredients. However, by adding the Oradisc(TM) technology to these films, the resulting products will not only be fast acting, but will also offer sustained release of actives over several hours. These new products will therefore have properties that neither technology could achieve on its own.

Patients with nausea are often unable to take tablets effectively, so an in-the-mouth instant release anti-emetic offers a good solution to treat acute nausea and the OraDisc technology provides a longer term solution to the problem. This is a therapeutic area with a large unmet need. BioProgress have a large amount of in-house expertise in this area and ULURU has significant experience in the development of film technology through FDA approval.

Richard Trevillion, CEO of BioProgress, said: "We are delighted to be entering a strategic partnership with ULURU. The technologies from both companies are complementary and can work in combination to create products with both instant release and sustained release characteristics. This approach has the potential to create real therapeutic value and enhance the effectiveness of medicines."

Kerry Gray, President and CEO of ULURU Inc. stated, "This partnership is exciting for both companies as we can access the development strengths and resources of both groups. Our ability to combine instant release with sustained delivery over an extended period has the potential to create considerable value. We will be applying proven technologies to existing medicines with the objective of dramatically improving the resultant profile."

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.

About BioProgress plc:

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL(TM) polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to http://www.bioprogress.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including but not limited to statements made relating to the establishment of strategic joint development agreements and the risks and uncertainties associated with product development activities. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company Kerry P. Gray President & CEO Terry K. Wallberg Vice President & CFO [phone] SOURCE ULURU Inc.

Kerry P. Gray, President & CEO, or Terry K. Wallberg, Vice President & CFO, both of ULURU INC., [phone]

http://www.prnewswire.com

Copyright (C) 2006 PR Newswire. All rights reserved.





ULURU Inc. verkündet strategische gemeinsame Entwicklung Vereinbarung mit BioProgress plc

DALLAS, 4. Mai 2006 /PRNewswire-FirstCall über COMTEX Nachrichten Netz --
ULURU Inc. (OTC Anschlagbrett: ULURE) („ULURU“) verkündete heute, daß es einen gemeinsamen strategischen Entwicklung Vertrag mit dem pharmazeutischen Spezialgebiet und healthcare Firma geschlossen hat, BioProgress plc (Nasdaq: BPRG). Die Firmen arbeiten zuerst zusammen, um ein antiemetisches Produkt für die Entlastung von übelkeit mit einer Kombination der Filmtechnologie BioProgress und Oradisc ULURUS zu entwickeln (TM) der Drogeanlieferung Technologie. Dieses Verhältnis fährt dann fort, weitere therapeutische Produkte zu entwickeln.

ULURU wird auf die Entwicklung einer Mappe des Wundmanagements, Schönheitsoperation gerichtet und die Mundobachtprodukte, zum der Patienten und der Verbraucher bereitzustellen verbesserten klinische Resultate durch kontrollierte Anlieferung. OraDisc ULURUS (TM) Technologie ist eine erfinderische erodible Filmtechnologie, die an den Schleimhäuten haftet, das unterstützte Freigabe von actives in die Körperzirkulation über eine Zeitdauer von einigen Stunden erlaubt.

Die neuen Produkte werden erwartet, um der Strecke In-döffnung BioProgress der Filmstreifen, die zu ähneln sich sofort auflösen und geben die eingebetteten Aktivsubstanzen frei. Jedoch indem sie die Oradisc (TM) Technologie diesen Filmen hinzufügen, sind die resultierenden Produkte nicht nur schnelles Fungieren, aber bieten auch unterstützte Freigabe von actives über einigen Stunden an. Diese neuen Produkte haben folglich Eigenschaften, die auch nicht Technologie eigenständig erzielen könnte.

Patienten mit übelkeit sind häufig nicht imstande, Tabletten effektiv zu nehmen, also Angebote eines In-döffnung stellt sofortige Freigabe-Antiemetikums eine gute Lösung, zum der akuten übelkeit und der OraDisc Technologie zu behandeln eine längerfristige Lösung zum Problem zur Verfügung. Dieses ist ein therapeutischer Bereich mit einer großen unmet Notwendigkeit. BioProgress haben eine große Menge innerbetriebliche Sachkenntnis in diesem Bereich und ULURU hat bedeutende Erfahrung in der Entwicklung der Filmtechnologie durch FDA-Zustimmung.

Richard Trevillion, CEO von BioProgress, sagte: „Wir werden erfreut, eine strategische Teilhaberschaft mit ULURU einzutragen. Die Technologien von beiden Firmen sind ergänzend und können in der Kombination arbeiten, um Produkte mit sofortiger Freigabe und unterstützten Freigabeeigenschaften herzustellen. Diese Annäherung hat das Potential, realen therapeutischen Wert zu verursachen und die Wirksamkeit von Medizin zu erhöhen.“

Das Kerry Grau, Präsident und CEO von ULURU Inc. angegeben, „diese Teilhaberschaft ist für beide Firmen aufregend, wie wir die Entwicklung Stärken und die Betriebsmittel beider Gruppen zugänglich machen können. Unsere Fähigkeit, sofortige Freigabe mit unterstützter Anlieferung über einen ausgedehnten Zeitraum zu kombinieren hat das Potential, beträchtlichen Wert zu verursachen. Wir werden anwenden nachgewiesene Technologien an vorhandener Medizin mit der Zielsetzung von das resultierende Profil drastisch verbessern.“

Über ULURU Inc.:

ULURU Inc. ist eine auftauchende Spezialgebiet pharmazeutische Firma, die auf die Entwicklung einer Mappe des Wundmanagements gerichtet wird, verbesserten Schönheitsoperation und Munddie obachtprodukte, zum der Patienten und der Verbraucher bereitzustellen klinische Resultate durch die kontrollierte Anlieferung, die seine erfinderische transmucosal Anlieferung System und Hydrogel Nanoparticle gesamte Technologie verwendet.

Über BioProgress plc:

BioProgress plc ist ein erfinderisches Spezialgebiet, das pharmazeutisch sind und das healthcare Geschäft, das um seine Plattformtechnologien Polymer-Plastik und Filmin den systemen gegründet wird. Verzeichnet auf ZIEL Londons im Mai 2003 und auf US Nasdaq im Oktober 2004, hat die Firma über 80 bewilligten Patenten oder in der Anwendung innerhalb 24 Patentfamilien und hat Produktentwicklung Vereinbarungen und strategische Bündnisse mit einigen globalen Firmen. Als praktisch integriertes Geschäft hat BioProgress Verkäufe und Marketing-Betriebsmittel innerhalb Europas und der US als Produkteinführung Einheit für seine eigenen pharmazeutischen Produkte erworben. Das Geschäft fährt fort, erfinderische Anlieferung Einheiten mit seiner XGEL (TM) Polymer-Plastik Technologie zu entwickeln und ersetzt die Notwendigkeit, Tier-abgeleitete Gelatine in den pharmazeutischen und healthcare Produkten zu benutzen. Für weitere Informationen bitte gehen zu http://www.bioprogress.com.

Dieses Pressekommuniquã# enthält bestimmte Aussagen, die innerhalb der Bedeutung des Abschnitts 27a der Sicherheiten Tat von 1933 Vorwärts-schauen, wie geändert, und die die Gefahren und Ungewißheiten miteinbeziehen und aber einschließen, begrenzt nicht auf die Aussagen abgegeben in bezug auf die Einrichtung der strategischen gemeinsamen Entwicklung Vereinbarungen und der Gefahren und die Ungewißheiten verbunden mit Produktentwicklung Tätigkeiten. Diese Aussagen sind abhängig von den zahlreichen Gefahren, schließen ein, aber begrenzt nicht auf die Gefahren, die im jährlichen Bericht der Firma über Form 10-K für das Jahr beendet 31. Dezember 2004, im vierteljährlichen Bericht über Form 10-Q für das Viertel genau geschildert werden, das 30. September 2005 beendet wird und in anderen Reports, die von uns mit der Sicherheiten und Austausch-Kommission vorgelegt werden.

Kontakt: Grauer Präsident des Firmakerry-P. u. CEO Terry K. Wallberg Vizepräsident u. CFO [phone] SOURCE ULURU Inc.

Grau, Präsident u. CEO oder Terry K. Wallberg, Vizepräsident u. CFO, beide des Kerry-P. von ULURU INC., [phone]

http://www.prnewswire.com

Copyright (c) Fotorezeptor 2006 Newswire. Alle Rechte vorbehalten.

[Andreito]

weis einer was hier los ist??? seit 2 tagen kein handel...

[Andreito]

weis einer wieso das volumen heute so angestiegen ist???

46.250 stuecke kurs 1,5 usd

[Andreito]

kann einer was mit dem 10QSB filing was anfangen das gestern veroeffentlicht wurde???

[Andreito]

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-QSB


[X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934.


For the quarterly period ended: March 31, 2006


OR


[_] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934.


For the transition period from : to


Commission File Number: 000-49670

ULURU INC.


(Name of Small Business Issuer in its Charter)

Nevada 41-2118656
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)



4452 Beltway Drive
Addison, Texas 75001
(Address of principal executive offices)


Registrant's telephone number, including area code: [phone]


Securities registered pursuant to Section 12(b) of the Act: None


Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.001 par value


Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]


Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes [ ] No [X]


The number of outstanding shares of registrant's Common Stock on May 9, 2006 was 12,844,311.


Transitional Small Business Disclosure Format. Yes [ ] No [X]




--------------------------------------------------------------------------------

Table of Contents



ULURU INC.


FORM 10-QSB


For the Quarterly Period Ended MARCH 31, 2006


TABLE OF CONTENTS
Page
PART I FINANCIAL INFORMATION

Item 1. Financial Statements 3

Condensed Consolidated Balance Sheet, March 31, 2006 (unaudited) 3
Unaudited Condensed Consolidated Statement of Operations for the three months ended March 31, 2006 4
Unaudited Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2006 5
Notes to Financial Statements (unaudited) 6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18

Item 3. Controls and Procedures 23

PART II OTHER INFORMATION

Item 1. Legal Proceedings 23

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23

Item 3. Defaults Upon Senior Securities 24

Item 4. Submission of Matters to a Vote of Security Holders 24

Item 5. Other Information 24

Item 6. Exhibits 25

Signatures 25


















- 2 -
--------------------------------------------------------------------------------

Table of Contents

PART 1 - FINANCIAL INFORMATION


ITEM 1. FINANCIAL STATEMENTS


ULURU INC.
CONDENSED CONSOLIDATED BALANCE SHEET
AS AT MARCH 31, 2006
(unaudited)


ALL ASSETS ARE PLEDGED AS COLLATERAL UNDER NOTES PAYABLE


ASSETS
Current Assets
Cash $ 587,674
Cash in escrow account 128,045
Accounts receivable - trade 81,823
Accounts receivable - other 42,823
Inventory 115,219
Prepaid expenses 207,887
Total Current Assets 1,163,471

Property, Plant & Equipment, net 410,858

Other Assets
Patents, net 12,046,214
Licensing rights, net 485,965
Deferred financing costs, net 1,012,602
Deposits 19,129
Total Other Assets 13,563,910

TOTAL ASSETS $ 15,138,239

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current Liabilities
Accounts payable $ 597,975
Accrued liabilities 51,317
Shareholder advance 1,484
Royalty advance 309,797
Accrued interest 393,068
Asset purchase obligation, net 3,520,061
Total Current Liabilities 4,873,702

Long Term Debt
Asset purchase obligation, net - less current portion 866,804
Notes Payable 13,012,829
Total Long Term Debt 13,879,633

Total Liabilities 18,753,335

STOCKHOLDERS' EQUITY (DEFICIT)

Preferred stock, $.001 par value, 20,000 shares
authorized, none issued --

Common Stock: $ 0.001 par value, 200,000,000 shares authorized;
12,844,311 issued and outstanding 12,844
Paid-in capital 214,891
Retained earnings (deficit) (3,842,831 )
Total Stockholders’ Equity (Deficit) (3,615,096 )

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 15,138,239

The accompanying notes are an integral part of these consolidated financial statements.






- 3 -
--------------------------------------------------------------------------------

Table of Contents



ULURU INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2006
(unaudited)



REVENUES
Royalty income $ 182,172
Other 84,992
Total Revenues $ 267,164


COSTS AND EXPENSES
Research and development 476,396
General and administrative 283,029
Commitment fee - Standby equity agreement 1,787,940
Depreciation and amortization 263,073
Total Costs and Expenses 2,810,438

OPERATING LOSS (2,543,274 )

Other Income (Expense)
Interest income 8,380
Interest Expense (374,003 )


NET INCOME (LOSS) $ (2,908,897 )


Basic and diluted net (loss) per common share $ (.26 )

WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING 11,331,100


The accompanying notes are an integral part of these consolidated financial statements.






- 4 -
--------------------------------------------------------------------------------

Table of Contents

ULURU INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2006
(unaudited )



OPERATING ACTIVITIES :
Net (loss) from operations $ (2,908,897 )

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 263,073
Commitment fee - Standby equity agreement 1,787,940
Imputed interest expense 105,786

Change in operating assets and liabilities
Accounts receivable 52,559
Inventory (28,600 )
Prepaid expenses 13,267
Deposits (19,129 )
Accounts payable (112,065 )
Royalty advance (159,258 )
Accrued interest 36,944
Total Adjustments 1,940,517

Net Cash (Used) by Operating Activities (968,380 )

INVESTING ACTIVITIES :
Increase in fixed assets (42,469 )
Cash received in recapitalization of the company 128,045

Net Cash Provided by Investing Activities 85,576

FINANCING ACTIVITIES :

Repayment of note payable (11,833 )

Net Cash (Used) by Financing Activities (11,833 )

Net (Decrease) in Cash (894,637 )

Cash, beginning of period 1,610,357
Cash, end of period $ 715,719



Supplemental Schedule of Noncash
Investing and Financing Activities :
Non-monetary net liabilities assumed in a recapitalization of the Company on March 31, 2006.
Liabilities assumed $ 13,694,962
Less : Non-cash assets 12,006,690
Less : Cash received in recapitalization 128,045
Total non-monetary net liabilities assumed $ 1,560,227

OTHER SUPPLEMENTAL INFORMATION
Cash Paid for Interest $ 237,777

The accompanying notes are an integral part of these consolidated financial statements.








- 5 -
--------------------------------------------------------------------------------

Table of Contents



ULURU INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2006
(unaudited)




NOTE 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of March 31, 2006 and the results of its operations for the three months ended March 31, 2006 and cash flows for the three months ended March 31, 2006 have been made. Operating results for the three months ended March 31, 2006 are not necessarily indicative of the results that may be expected for the year ended December 31, 2006.


These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Definitive Information Statement on Schedule 14C filed March 1, 2006, and Form 10-KSB for the year ended December 31, 2005.




NOTE 2. BASIS OF PRESENTATION


History


ULURU Inc. (“ULURU” or the “Company”), formerly Oxford Ventures, Inc, Casinos of The World, Inc., Clean Way Corporation, Trader Secrets.Com, and VOIP Technology, Inc. was in the development stage as defined in Financial Accounting Standards Board Statement No. 7 as of December 31, 2005. It is a Nevada corporation, formed on September 17, 1987. From inception through March 31, 2006, it has had no substantial earned revenues from any planned operations.


In December 2003, ULURU acquired technology in process of development in the entertainment industry from several persons in exchange for cash and a majority interest in the Company. During 2004 ULURU obtained additional financing, entered into a standby equity distribution agreement, and completed a registration statement on Form SB-2 on December 14, 2004.


On October 12, 2005, ULURU entered into a merger agreement with ULURU Inc., a Delaware corporation (“ULURU Delaware”) and Uluru Acquisition Corp., a wholly-owned Delaware subsidiary of ULURU formed on September 29, 2005. Under the terms of the agreement, Uluru Acquisition Corp. merged into ULURU Delaware, after ULURU Delaware had acquired the net assets of the topical component of Access Pharmaceuticals, Inc., under Section 368 (a) (1) (A) of the Internal Revenue Code, “ a statutory merger or consolidation”.





- 6 -
--------------------------------------------------------------------------------

Table of Contents



As a result of the merger, ULURU acquired all of the issued and outstanding shares of ULURU Delaware under a stock exchange transaction, and ULURU Delaware became a wholly-owned subsidiary of ULURU, its legal parent. However, for financial accounting and reporting purposes, ULURU Delaware is treated for accounting purposes as the acquirer and is consolidated with its legal parent, similar to the accounting treatment given in a recapitalization. For accounting presentation purposes only, ULURU’s net assets are treated as being acquired by ULURU Delaware at fair value as of the date of the stock exchange transaction, and the financial reporting thereafter will not be that of a development stage enterprise, since ULURU Delaware had substantial earned revenues from planned operations. Both companies have a December 31 year end.


All intercompany transactions have been eliminated in the condensed consolidated financial presented herewith.


On March 29, 2006, ULURU filed a Certificate of Amendment to the Articles of Incorporation in Nevada. This Certificate of Amendment authorized a 400:1 reverse stock split to occur so that in exchange for every 400 outstanding shares of common stock that each shareholder had at the close of business on March 29, 2006, the shareholder would receive one share of common stock. As a result of this reverse stock split, ULURU’s issued and outstanding common stock was reduced from 340,396,081 pre-split shares of common stock to 851,011 post-split shares which includes an additional 21 shares for fractional interests. The Certificate of Amendment also authorized a decrease in authorized shares of common stock from 400,000,000 shares, par value $.001 each, to 200,000,000, par value $.001 each, and authorized up to 20,000 shares of Preferred Stock, par value $.001.


On March 31, 2006, ULURU filed a Certificate of Amendment to the Articles of Incorporation in Nevada to change its name from “Oxford Ventures, Inc.” to “ULURU INC.”.


On March 31, 2006, ULURU acquired, through its wholly-owned subsidiary (Uluru Acquisition Corporation) a 100% ownership interest in ULURU Delaware through a merger of ULURU Delaware into Uluru Acquisition Corporation. ULURU acquired ULURU Delaware in exchange for 11,000,000 shares of ULURU’s common stock. All securities issued pursuant to the merger are “restricted” stock and are subject to a two year Lock-up Agreement as well as all applicable re-sale restrictions specified by federal and state securities laws. The shareholders of ULURU immediately prior to the merger retained 851,011 shares of common stock.


The aggregate amount of shares of common stock issuable to the shareholders of ULURU Delaware pursuant to the merger represented 92.8% of the issued and outstanding shares of ULURU’s common stock. Under the terms of the Agreement and Plan of Merger and Reorganization executed on October 12, 2005, the pre-merger stockholders of ULURU owned an aggregate of 7.2% of the issued and outstanding shares of ULURU’s common stock immediately after the merger.


At the effective time of the Merger, the members of the ULURU Delaware Board of Directors holding office immediately prior to the merger became ULURU’s directors, and all persons holding offices of ULURU Delaware at the effective time, continue to hold the same offices of the surviving corporation. Simultaneously, ULURU’s directors and officers immediately prior to the closing of the Merger resigned from all of their respective positions with ULURU.





- 7 -
--------------------------------------------------------------------------------

Table of Contents



NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


Use of Estimates in the Preparation of Consolidated Financial Statements


The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates and assumptions. These differences are usually minor and are included in our consolidated financial statements as soon as they are known. ULURU’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.


Cash Equivalents


The Company considers all highly liquid investments with the original maturities of three months or less to be cash equivalents.


Concentrations of credit risk


The Company is subject to concentrations of credit risk on their temporary cash investments due to the use of a limited number of banking institutions. The Company mitigates this risk by placing temporary cash investments with major financial institutions, which have all been accorded high ratings by primary rating agencies


Loss per Common Share


Basic loss per common share is calculated based upon the weighted average number of common shares outstanding during the period in accordance with the Statement of Financial Accounting Standards Statement No. 128, “Earnings per Share” after giving effect to all stock splits including the 400 for 1 reverse stock split approved by the Company’s stockholders on March 29, 2006.


Income Taxes


ULURU uses the liability method of accounting for income taxes pursuant to Statement of Financial Accounting Standards Board Opinion No. 109. Under this method, deferred income taxes are recorded to reflect the tax consequences in future periods of temporary differences between the tax basis of assets and liabilities and their financial statement amounts at year-end.


Revenue recognition


The Company recognizes revenue from license payments not tied to achieving a specific performance milestone ratably over the period over which the Company is obligated to perform services. The period over which the Company is obligated to perform services is estimated based on available facts and circumstances. Determination of any alteration of the performance period normally indicated by the terms of such agreements involves judgment on management’s part.





- 8 -
--------------------------------------------------------------------------------

Table of Contents



The Company recognizes revenue from performance payments, when such performance is substantially in the Company’s control and when the Company believes that completion of such performance is reasonably probable, ratably over the period over which the Company estimates that it will perform such performance obligations.


Substantive at-risk milestone payments, which are based on achieving a specific performance milestone when performance of such milestone is contingent on performance by others or for which achievement cannot be reasonably estimated or assured, are recognized as revenue when the milestone is achieved and the related payment is due, provided that there is no substantial future service obligation associated with the milestone.


Revenue in connection with license arrangements is recognized over the term of the arrangement and is limited to payments collected or due and reasonably assured of collection. In circumstances where the arrangement includes a refund provision, the Company defers revenue recognition until the refund condition is no longer applicable unless, in the Company’s judgment, the refund circumstances are within its operating control and unlikely to occur.


The Company recognizes revenue and related costs from the sale of its products at the time the products are shipped to the customer.


Sponsorship income has no significant associated costs since it is being paid only for information pertaining to a specific research and development project in which the sponsor may become interested in acquiring products developed thereby.


Payments received in advance of being recognized as revenue are deferred. Contract amounts are not recognized as revenue until the customer accepts or verifies the research results.


Property and Equipment


Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Estimated useful lives for property and equipment categories are as follows:


Furniture , fixtures, and laboratory equipment 7 years
Computer and office equipment 5 years
Computer software 3 years
Leasehold improvements Lease term



Deferred Charge


From time to time fees are payable to the Federal Drug Administration in connection with new drug applications submitted by ULURU. Such fees are considered deferred charges since they are not recoverable unless the related drug is accepted and approved by the FDA for use or sale by ULURU to the general public. Such fees are being amortized ratably over the period of 12 months beginning with the month such fees were paid.





- 9 -
--------------------------------------------------------------------------------

Table of Contents



Patents and Applications


We expense internal patent and application costs as incurred because, even though we believe the patents and underlying processes have continuing value, the amount of future benefits to be derived therefrom are uncertain. Purchased patents are capitalized and amortized over the life of the patent.


Allowance for Doubtful Accounts


ULURU estimates the collectibility of its trade accounts receivable. In order to assess the collectibility of these receivables, ULURU monitors the current creditworthiness of each customer and analyzes the balances aged beyond the customer’s credit terms. Theses evaluations may indicate a situation in which a certain customer cannot meet its financial obligations due to deterioration of its financial viability, credit ratings or bankruptcy. The allowance requirements are based on current facts and are reevaluated and adjusted as additional information is received. Trade accounts receivable are subject to an allowance for collection when it is probable that the balance will not be collected. As of March 31, 2006, no allowance for collectibility was needed.


Research and Development Expenses


Pursuant to SFAS No. 2, “Accounting for Research and Development Costs,” our research and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and related expense, lab supplies, preclinical, development cost, clinical trial expense, outside manufacturing and consulting expense. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired. As of March 31, 2006, there were no such capitalized materials, equipment or facilities.


Inventory


Raw materials and finished goods inventories are directly attributable to the Business. Inventories are stated at the lower of cost or market value. Raw material inventory cost is determined on the first-in, first-out method. Costs of finished goods are determined by an actual cost method.




NOTE 4. GOING CONCERN


ULURU’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. It has sustained operating losses since inception and has a deficit in working capital and stockholders’ equity. ULURU’s ability to continue in existence is dependent on its ability to develop additional sources of capital and/or achieve profitable operations.


Management’s plans in regard to achieving profitable operations will take time and involve commercializing products for advancing topical delivery, wound management, burn care and plastic surgery. The Company’s efforts are in the development of novel topically applied therapeutics based primarily on the adaptation of existing therapeutic agents using its proprietary drug delivery platforms to improve clinical outcomes.





- 10 -
--------------------------------------------------------------------------------

Table of Contents

We believe that our products that require extensive sales efforts directed both at the consumer and the general practitioner can only compete successfully if marketed by a company having expertise and a strong presence in the therapeutic area or in direct to consumer marketing. Consequently, our business model is to form strategic alliances with major or regional pharmaceutical companies for products to compete in these markets. Management believes that our development risks should be minimized and that the technology potentially could be more rapidly developed and successfully introduced into the marketplace by adopting this strategy.


The Company plans to establish a sales and marketing organization to commercialize our wound management, burn care, and plastic surgery products. The Company believes that a small dedicated sales and marketing organization can effectively commercialize our products. To achieve this objective, ULURU plans on acquiring additional complimentary wound management and plastic surgery products. We plan to add additional products to our existing portfolio through the addition of numerous wound management compounds to our nanoparticle aggregate dressing.


We plan in the near term to file a registration statement with the Securities and Exchange Commission to enable us to finance our business plan.


The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.




NOTE 5. RELATED PARTY TRANSACTIONS


On January 9, 2006 ULURU Delaware remitted $230,556 to Uluru in payment of its interest obligation to ULURU, which included payments due as of November 12 and December 12, 2005. There were no principal payments on related party loans during the first quarter 2006.




NOTE 6. INVENTORY


A summary of inventory as of March 31, 2006 follows:


Net Book Value
Inventory - Amlexanox (Raw Material) $ 77,710

Inventory - Work in Progress (Aphthasol) 37,509

--------------------------------------------------------------------------------

Total $ 115,219





NOTE 7. PREPAID EXPENSES


A summary of prepaid expenses as of March 31, 2006 follows:


Net Book Value
Insurance (Property, Liability, Auto) $ 44,699
Insurance (Medical) 10,090
Research & Development 153,098

--------------------------------------------------------------------------------

Total $ 207,887






- 11 -
--------------------------------------------------------------------------------

Table of Contents



NOTE 8. PROPERTY AND EQUIPMENT


A summary of property and equipment as of March 31, 2006 follows:


Cost Accumulated Depreciation and Amortization Net Book Value
Furniture and laboratory equipment $ 399,011 $ 27,022 $ 371,989
Computer and office equipment 31,500 2,037 29,463
Computer software 4,108 114 3,994
Leasehold improvements 5,412 --- 5,412
Total $ 440,031 $ 29,173 $ 410,858





NOTE 9. PATENTS AND LICENSING RIGHTS


On October 11, 2005 the Company purchased certain patents and licensing rights from Access Pharmaceuticals Inc. As part of the asset purchase, the Company assigned certain values to each intangible asset based upon expected future earning for each technology taking into consideration criteria such as patent life, approved products for sale, the existence of marketing, manufacturing, and distribution agreements, and development costs.


The Company derived each asset value based on expected cash flows from each technology over an 8 year period, using the aforementioned criteria as well as varying valuation multiples for determining a terminal value and varying discount rates for risk tolerance. All of these criteria are typically used for valuation analyses within the pharmaceutical industry. Synopses for each technology valuation are as follows:


ZINDACLIN
· Approved product (Residerm)
· Manufacturing, distribution, and marketing agreement with ProStrakan Ltd that includes world-wide territory (except United States). Not currently marketed in United States.
· Patent expires in 11/28/2020

Net Present Value Discount 15.0 %
Value Assigned $ 1,921,701


AMLEXANOX (Aphthasol)
· Approved product (Aphthasol)
· Manufacturing, distribution, and marketing agreement with various partners for territories to include United Kingdom, Ireland, Europe, Middle East, and Far East. Discus Dental has territorial rights for the United States.
· Patent expires in 11/08/2011

Net Present Value Discount 35.0 %
Value Assigned $ 1,801,595


AMLEXANOX (OraDisc A)
· Approved product (OraDisc A)
· Manufacturing process current in final phase of development.
· Distribution and marketing agreements with various partners for territories to include United Kingdom, Ireland, Europe, Middle East and Far East. Discus Dental has the territorial rights for the United States.
· Patent expires in 08/16/2021

Net Present Value Discount 35.0 %
Value Assigned $ 8,647,656


ORA DISC
· No approved products (excluding OraDisc A)
· Developing applications for commercialization of various products using technology are ongoing.
· Patent expires in 08/16/2021

Net Present Value Discount 50.0 %
Value Assigned $ 144,128


HYDROGEL NANOPARTICLE AGGREGATE
· No approved products
· Research and development for commercialization of various products using technology are ongoing.
· Patent and licensing rights expire in 11/06/2022

Net Present Value Discount 50.0 %
Value Assigned $ 500,000







- 12 -
--------------------------------------------------------------------------------

Table of Contents



A summary of patents and licensing rights as of March 31, 2006 follows:

Cost Accumulated Amortization Net Book Value
PATENTS
Zindaclin $ 1,921,701 $ 60,856 $ 1,860,845
Amlexanox (Aphthasol) 1,801,595 142,145 1,659,450
Amlexanox (OraDisc A) 8,647,656 261,507 8,386,149
OraDisc 144,128 4,358 139,770
Total Patents $ 12,515,080 $ 468,866 $ 12,046,214

LICENSING RIGHTS
Hydrogel Nanoparticle Aggregate $ 500,000 $ 14,035 $ 485,965





NOTE 10. DEFERRED FINANCING COSTS


On October 12, 2005 the Company incurred loan costs of $1,320,000 which are being amortized ratably over the two year term of the notes payable. A summary of the deferred financing costs as of March 31, 2006 follows:
Loan Costs Accumulated Amortization Net Book Value
Convertible debenture - Prenox LLC $ 1,000,000 $ 232,877 $ 767,123
Convertible debenture - Highgate House 320,000 74,521 245,479
Total $ 1,320,000 $ 307,398 $ 1,012,602





NOTE 11. STOCKHOLDERS’ EQUITY


Reverse Stock Split


On March 29, 2006, the Company amended its articles of incorporation to implement a 400 for 1 reverse stock split, a decrease in the authorized shares of common stock to 200 million from 400 million, and the authorization of up to 20,000 shares of Preferred stock, par value $.001 per share. Accordingly, all shares referred to in the accompanying consolidated financial statements and included in these Notes give retroactive effect to this authorization.




NOTE 12. INCOME TAXES


There was no current federal tax provision or benefit recorded for any period since inception, nor were there any recorded deferred income tax assets, as such amounts were completely offset by valuation allowances.





- 13 -
--------------------------------------------------------------------------------

Table of Contents



NOTE 13. THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS


Stock-Based Compensation


Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS 123R, Share-Based Payments (“SFAS No. 123(R)”), which is a revision of SFAS No. 123.


The value of each employee stock option granted is estimated on the grant date under the fair value method using the Black-Scholes option pricing model. For options granted after January 1, 2006, the Company amortizes the fair value on a straight-line basis. All options are amortized over the requisite service period of the awards, which are generally the vesting periods


There were no employee stock options granted during the three months ended March 31, 2006.


Stock-based awards issued to non-employees are accounted for using the fair value method and are remeasured to fair value at each period end until the earlier of the date that performance by the non-employee is complete or a performance commitment has been obtained. The fair value of each award to non-employees is estimated using the Black-Scholes option pricing model.


There were no non-employee stock options granted during the three months ended March 31, 2006.




NOTE 14. COMMITMENTS AND CONTINGENCIES


Legal Proceedings


On June 29, 2004, a complaint was filed against ULURU in the County Court, Denver County, Colorado. The complaint alleges that ULURU used a telephone facsimile machine, computer or other device to send unsolicited advertisements to the facsimile machine of Cache Valley Electric without having obtained the prior express permission or invitation to do so. The plaintiff in the action seeks recovery of up to $15,000. ULURU filed an answer to the complaint on July 29, 2004, and does not believe that the complaint has merit. No further action has been taken by either party as of March 31, 2006.


On January 31, 2005, a Default Judgment for $57,144 was filed against ULURU in the Superior Court of Maricopa County, Arizona. The judgment was for the benefit of TGR Properties, LLC, for damages that have been incurred as a result of the premature termination of the operating lease of the facilities in Mesa, Arizona. As of April 28, 2006, the balance due on this judgment is $122,406, which is included in accounts payable as of March 31 2006, includes post judgment legal fees, interest and collection costs.





- 14 -
--------------------------------------------------------------------------------

Table of Contents



NOTE 15. ASSET PURCHASE OBLIGATIONS


As part of the asset purchase from Access Pharmaceuticals, Inc. (“Access”) on October 11, 2005, the Company paid to Access $8,700,000 on October 11, 2005 and is obligated to pay Access $3,700,000 on October 11, 2006 and $1,000,000 on October 11, 2007, along with certain milestone payments based upon future events which may or may not occur. Pursuant to the terms of the Asset Purchase Agreement by the Company and Access none of the future payment obligations to Access have any interest accrual. For financial statement presentation, the Company has applied APB 21, Interest on Receivables and Payables , and calculated imputed interest, at 10% per annum, on the future payment obligations. A summary of the asset purchase obligations as of March 31, 2006 follows:
Gross Asset Purchase Obligations Imputed Interest Net Asset Purchase Obligations
Asset Purchase Obligation (Due 10/12/2006) $ 3,700,000 $ 179,939 $ 3,520,061
Asset Purchase Obligation (Due 10/12/2007) 1,000,000 133,196 866,804
Total $ 4,700,000 $ 313,135 $ 4,386,865

Less : current portion 3,700,000 179,939 3,520,061
Total Asset Purchase Obligation (Long-Term) $ 1,000,000 $ 133,196 $ 866,804





NOTE 16. DEBT AND EQUITY FINANCING


On October 12, 2005, the Company entered in a Securities Purchase Agreement to issue secured convertible debentures to Highgate House Funds, Ltd. and Prenox, LLC in an amount of up to $15,000,000 and to issue Highgate and Prenox warrants for up to 5 million shares (post-split) of ULURU’s common stock for a period of five years with an exercise price of $.01(post-split).


Also on October 12, 2005, ULURU issued a $10,000,000 secured convertible debenture to Prenox and a $3,000,000 secured convertible debenture (together, the "Debentures") to Highgate as well as the Warrants. ULURU used the majority of the proceeds from the Debentures to extend a loan, described below, to ULURU Delaware. The shares underlying the Warrants shall be included on a registration statement, described below, to be filed by ULURU with the Securities and Exchange Commission. In exchange for the purchase of the Debentures, ULURU granted Highgate and Prenox a security interest in all of its assets, including any assets ULURU acquires while the Debentures are outstanding, and has agreed to issue shares of common stock in an amount equal to five times the gross proceeds of the Debentures to be held in escrow in the event of a default under the Debentures (the "Escrow Shares").


The Debentures have a term of two years from the date of issuance and bear an interest rate of ten percent per annum, compounded monthly. ULURU may redeem the Debentures at any time prior to their maturity at a price equal to 120% of the face amount redeemed plus any accrued interest. Highgate and Prenox may at their option convert all or some of the Debentures plus any accrued and unpaid interest into shares of ULURU’s common stock at the price of $1.50 per share which is not considered to be a beneficial conversion feature.





- 15 -
--------------------------------------------------------------------------------

Table of Contents



On October 12, 2005, ULURU entered into a Bridge Loan and Control Share and Pledge Security Agreement, (the "Bridge Loan Agreement") with ULURU Delaware and its president. Pursuant to the Bridge Loan Agreement, ULURU loaned ULURU Delaware $10,700,000 in exchange for a secured debenture. In addition to granting the ULURU Delaware Debenture, ULURU Delaware granted a security interest in its assets to ULURU and the president pledged ULURU Delaware shares representing 54.5% of ULURU Delaware’s capital stock to ULURU. To entice Highgate and Prenox to enter into the Securities Purchase Agreement, ULURU assigned the Security Interest and the Pledged Shares to Prenox and Highgate pursuant to a Collateral Assignment Agreement entered into between ULURU, Highgate and Prenox.


A summary of the Notes Payable and Accrued Interest, as of March 31, 2006, follows:
Note Payable Accrued Interest
Note Payable - Prenox LLC $ 10,000,025 $ 249,155
Note Payable - Highgate House 3,000,000 143,913
Note Payable - Malvern Financial (Equipment) 12,804 -0-

Total $ 13,012,829 $ 393,068





NOTE 17. STANDBY EQUITY DISTRIBUTION AGREEMENT


On October 12, 2005, the Company entered into a new Standby Equity Distribution Agreement ("SEDA") with Cornell Capital Partners, LP (Cornell). Under the SEDA, Cornell committed to purchase over the course of two years from the date of the effectiveness of a registration statement described below up to $30,000,000 of the Registrant's common stock in increments of up to $1,000,000 (each such increment, an "Advance"). The purchase price for this common stock shall be 97% of the lowest daily volume weighted average price of the common stock during the five consecutive trading days after notice is given requesting an Advance.


The Company has agreed to file a registration statement with the Securities and Exchange Commission to register the resale of the Company’s common stock issued to Cornell pursuant to the SEDA. The registration statement shall also include the shares of common stock underlying the Warrants and the Escrow Shares. The Company is required to continuously maintain the effectiveness of the registration statement for a period of twenty four (24) months after its effective date.


The Company authorized for issuance at the time of the completion of the recapitalization and merger with ULURU Delaware 993,300 (post-split) shares of its common stock as a commitment fee to Cornell, valued at $1.80 per share for a total of $1,787,940, which was classified as an expense in the accompanying condensed consolidated financial statements for the quarter ended March 31, 2006.





- 16 -
--------------------------------------------------------------------------------

Table of Contents



NOTE 18. ESCROW ACCOUNT


An unrestricted escrow account was established for the net proceeds obtained from the 13 million dollars of debt financing provided to ULURU on October 12, 2005, most of which was used as a loan to ULURU Delaware. As of March 31, 2006 there was $128,045 in the account.




NOTE 19. 2006 EQUITY INCENTIVE PLAN


On March 31, 2006, ULURU adopted the 2006 Equity Incentive Plan. Under the plan, up to 2,000,000 shares of ULURU common stock may be issued. Some awards under the plan may link future payments to the awardee to the future value of a specified number of shares of common stock. The number of shares used for reference purposes in connection with these awards will be considered "delivered" for purposes of computing the maximum number of shares that may be delivered under the plan. If an award under the plan terminates without the shares subject thereto being delivered, the shares subject to such award will thereafter be available for further awards under the plan. All directors, officers, employees and non-employee service providers of ULURU are eligible to participate in the plan. No awards were made under this plan as of March 31, 2006.




NOTE 20. EMPLOYMENT AGREEMENTS


ULURU assumed, on March 31, 2006, three existing employment agreements (“Agreements”) between ULURU Delaware and certain key executives. The term of the agreement for the Chief Executive Officer is for three years with automatic annual renewal unless notice is provided by ULURU. The other two agreements have an initial term of one year with automatic annual renewals unless notice is provided by ULURU. The Agreements provide for compensation, incentives, and benefits that are commensurate with similar positions within the pharmaceutical industry.




NOTE 21. LEASE OBLIGATION


On January 31, 2006 the ULURU Delaware entered into a lease agreement for office and laboratory space in Addison, Texas. The monthly lease obligation of $9,034.53 commenced on April 1, 2006 and continues for eighty four (84) months.


Calendar Years Future Lease Expense

2006 $ 81,311
2007 108,414
2008 108,414
2009 108,414
2010 108,414
2011 & Beyond 243,934
Total $ 758,901






- 17 -
--------------------------------------------------------------------------------

Table of Contents

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATION


This Quarterly Report on Form 10-QSB contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and that involve risks and uncertainties, including, but not limited to the uncertainties associated with research and development activities, clinical trials, our ability to raise capital, our ability to repay our outstanding debt obligations, the timing of and our ability to achieve regulatory approvals, dependence on others to market our licensed products, collaborations, future cash flow, the timing and receipt of licensing and milestone revenues, our ability to achieve licensing and milestone revenues, the future success of our marketed products and products in development, our ability to achieve licensing milestones and other risks described below as well as those discussed elsewhere in this Form 10-QSB, documents incorporated by reference and other documents and reports that we file periodically with the Securities and Exchange Commission including our Form 10-KSB for the period ended December 31, 2005. Forward-looking statements contained in this Form 10-QSB include, but are not limited to those relating to anticipated product approvals and timing thereof, the terms of future licensing arrangements, our ability to secure additional financing for our operations, our ability to repay our outstanding debt obligations, our ability to fund our operations through December 31, 2006 with our current cash reserves and without accessing our SEDA, and our expected capital expenditures.


Business


ULURU Inc. (ULURU) is a Nevada corporation. We are an emerging pharmaceutical company focused on establishing a market leadership position in the development of wound management, plastic surgery and oral care products utilizing innovative drug delivery solutions to improve the clinical outcome of patients and provide a pharmacoeconomic benefit to healthcare providers. The first step in achieving this objective was the acquisition of the topical business component of Access Pharmaceuticals, Inc. which was completed on October 12, 2005. This acquisition resulted in the Company acquiring Aphthasol®, Zindaclin® and the Mucoadhesive Film technology and a fully paid exclusive worldwide license to the Nanoparticle Aggregate technology for all applications excluding injectable drug delivery devices. Utilizing this technology, three products have been approved for marketing in various global markets. In addition, numerous products are under development utilizing our Mucoadhesive Film and Nanoparticle Aggregate technologies.


Recent Developments


On May 3, 2006 the Company entered a Research Collaboration and Option Agreement with Dexo Biopharm Limited a subsidiary of BioProgress Plc. The objective of the collaboration is to develop a specified anti-emetic for the treatment of emesis utilizing our mucoadhesive film, OraDisc, and Dexo Biopharm Limited’s Instant Release Film technology. Under the terms of the collaboration the companies will share the development expense and the future revenues.





- 18 -
--------------------------------------------------------------------------------

Table of Contents



Other Key Developments


On October 12, 2005 the Company entered into a Securities Purchase Agreement to issue Secured Convertible Debentures to Prenox, LLC and Highgate House Funds, Limited in an amount of up to $15,000,000. Under the Securities Purchase Agreement on October 12, 2005 the Company issued a $10,000,000 secured convertible debenture to Prenox, LLC (“Prenox”) and a $3,000,000 secured convertible debenture to Highgate House Funds, Ltd. (“Highgate”) as well as Warrants to purchase up to 5,000,000 shares of the company for a period of 5 years with an exercise price of $0.01. The shares underlying the Debentures and Warrants shall be included on a registration statement to be filed by the company with the Securities and Exchange Commission. In exchange for the purchase of the Debentures, the Company granted Prenox and Highgate a security interest in all of its assets, including any assets the Company acquires while the Debentures are outstanding. The sale of the Debentures and Warrants was made under Section 4(2) of the Securities Act of 1933.


The Debentures have a term of two years from the date of issuance and bear an interest rate of ten percent per annum, compounded monthly. The company may redeem the Debentures at any time prior to their maturity at a price equal to 120% of the face amount redeemed plus any accrued interest. Prenox and Highgate may at their option convert all or some of the Debenture plus any accrued and unpaid interest into shares of the Company’s common stock at the price of $1.50 per share.


Also, on October 12, 2005 the Company entered into a Standby Equity Distribution Agreement (“SEDA”) with Cornell Capital Partners, LP. Under the SEDA, Cornell committed to purchase over the course of two years from the date of the effectiveness of a registration statement up to $30,000,000 of the Company’s common stock in increments up to $1,000,000.


We were founded in Nevada in 1987 as Casinos of the World, Inc. In 1993 the Company’s name was changed to Clean Way Corporation, further changing its name to Trader.Secrets.com, Inc. in 1999, VOIP Technology, Inc. in 2000 and ultimately ULURU Ventures, Inc. in 2002. In 2006 we merged with ULURU Inc. a private Delaware Corporation, and changed our name to ULURU Inc. Our principal executive office is located at 4452 Beltway Drive, Addison TX 75001. Our telephone number is [phone].


Employees


As of March 31, 2006, we have 10 full-time and 3 part-time employees. Of these employees, 8 are directly engaged in or directly support research and development activities of which 5 have advanced scientific degrees, two directly support commercial and business development activities and 2 are in administrative positions. Our employees are not represented by a labor union and are not covered by a collective bargaining agreement. Management believes that we maintain good relations with our personnel. We compliment our internal expertise with external scientific consultants, university research laboratories and contract manufacturing organizations that specialize in various aspects of drug development including clinical development, regulatory affairs, toxicology, preclinical testing and process scale-up.





- 19 -
--------------------------------------------------------------------------------

Table of Contents



Web Availability


We make available free of charge through our web site, www.uluruinc.com , our annual reports on Form 10-KSB and other reports required under the Securities and Exchange Act of 1934, as amended, as soon as reasonably practicable after such reports are filed with, or furnished to, the Securities and Exchange Commission as well as certain of our corporate governance policies, including the charters for the Board of Director’s corporate governance committees and our code of ethics, corporate governance guidelines and whistleblower policy. We will provide to any person without charge, upon request, a copy of any of the foregoing materials. Any such request must be made in writing to ULURU Inc., 4452 Beltway Drive Addison, TX 75001 attn: Investor Relations.




LIQUIDITY AND CAPITAL RESOURCES


We have funded our operations primarily through private sales of convertible debentures and our principal source of liquidity is cash and cash equivalents. Contract research, products sales, royalty payments, licensing fees and milestone payments from corporate alliances have, and are expected in the future to, also provide funding for operations. As of March 31, 2006 our cash and cash equivalents and short-term investments were $715,719 and our working capital (current assets less current liabilities) was ($3,890,172). Our working capital at March 31, 2006 represented a decrease of $1,011,780 compared to our working capital as of December 31, 2005 of ($2,878,392). The decrease in working capital was primarily due to the loss from operations for the three months ended March 31, 2006.


As of March 31, 2006 the company did not have enough capital to achieve it’s near, medium or long-term goals. The available cash together with the $2 million the company is entitle to receive upon the effectiveness of a registration statement are expected to be sufficient to fund operation through December 31, 2006 assuming no access to the SEDA or additional financings. We plan to access the SEDA and /or have additional financings in 2006.


As part of the asset purchase from Access Pharmaceuticals, Inc. (“Access”) on October 11, 2005, the Company paid to Access $8,700,000 on October 11, 2005 and is obligated to pay Access $3,700,000 on October 11, 2006 and $1,000,000 on October 11, 2007, along with certain milestone payments based upon future events which may or may not. Pursuant to the terms of the Asset Purchase Agreement by the Company and Access none of the future payment obligations to Access have any interest accrual.


On October 12, 2005 the Company entered into a Securities Purchase Agreement to issue Secured Convertible Debentures to Prenox, LLC and Highgate House Funds, Limited in an amount of up to $15,000,000. Under the Securities Purchase Agreement on October 12, 2005 the Company issued a $10,000,000 secured convertible debenture to Prenox, LLC (“Prenox”) and a $3,000,000 secured convertible debenture to Highgate House Funds, Ltd. (“Highgate”) as well as Warrants to purchase up to 5,000,000 shares of the company for a period of 5 years with an exercise price of $0.01. The shares underlying the Debentures and Warrants shall be included on a registration statement to be filed by the company with the Securities and Exchange Commission. In exchange for the purchase of the Debentures, the Company granted Prenox and Highgate a security interest in all of its assets, including any assets the Company acquires while the Debentures are outstanding. The sale of the Debentures and Warrants was made under Section 4(2) of the Securities Act of 1933.



- 20 -
--------------------------------------------------------------------------------

Table of Contents





The Debentures have a term of two years from the date of issuance and bear an interest rate of ten percent per annum, compounded monthly. The company may redeem the Debentures at any time prior to their maturity at a price equal to 120% of the face amount redeemed plus any accrued interest. Prenox and Highgate may at their option convert all or some of the Debenture plus any accrued and unpaid interest into shares of the Company’s common stock at the price of $1.50 per share.


Also, on October 12, 2005 the Company entered into a Standby Equity Distribution Agreement (“SEDA”) with Cornell Capital Partners, LP. Under the SEDA, Cornell committed to purchase over the course of two years from the date of the effectiveness of a registration statement up to $30,000,000 of the Company’s common stock in increments up to $1,000,000.


Since our inception we have incurred negative cash flow from operations and anticipate for the balance of 2006 to continue to expend funds to advance our product developments, license additional products and establish a sales and marketing operation to commercialize our wound care products. Our expenses have exceeded our revenue, resulting in an accumulated deficit as of March 31, 2006 of ($3,665,159). We expect that our existing capital resources (including $2 million expected to be received upon the effectiveness of a registration statement) and funds available under the Securities Purchase Agreement will be adequate to fund our operations through 2006, assuming no access to the SEDA or additional financings. We plan to access the SEDA and/or have additional financings. We cannot assure investors that we will be able to raise additional capital, access the SEDA or that we will be able to generate significant product revenue or achieve or sustain profitability.


Our future capital requirements and adequacy of available funds will depend on many factors including:


· Our ability to raise financing in order to continue our operations
· The ability to successfully commercialize our wound management and burn care products and the market acceptance of these products
· The ability to establish and maintain collaborative arrangements with corporate partners for the research, development and commercialization of certain product opportunities
· Continued scientific progress in our development programs
· The costs involved in filing, prosecuting and enforcing patent claims
· Competing technological developments
· The cost of manufacturing and production scale-up
· Successful regulatory filings
· The ability to convert, repay or restructure our outstanding convertible notes






- 21 -
--------------------------------------------------------------------------------

Table of Contents



RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2006


Total Revenues
Revenues for first quarter were $267,164, highlighted by ramp-up of licensing royalties for Aphthasol with Discus Dental ($159,258), Zindaclin royalties with ProStrakan ($22,914), ongoing sponsored wound care research with University of Texas Southwestern ($34,992), and a development fee payment ($50,000) from Glaxo Smith Klein for our OraDisc technology.


Costs and Expenses
Research and development expense ($476,396) included primarily salaries/taxes/benefits ($223,554) as well as specific costs associated with the continuing development of our technologies:

$ 139,654 OraDisc
88,643 Wound Care - Nanoparticle
6,042 Aphthasol & other technologies
$ 234,339



General and administrative expense ($283,029) consists primarily of salaries/taxes/benefits ($171,080), professional fees for legal and accounting ($36,200), legal fees for patent applications ($19,805), travel and entertainment ($16,669), insurance ($12,275), and occupancy/utility costs ($11,895).


Commitment fee expense ($1,787,940) consists of a commitment fee to Cornell Capital for the successful completion of the merger on March 31, 2006. On April 18, 2006, the Company issued a certificate for 993,300 shares of common stock in payment of the commitment fee.


Depreciation and amortization includes the following:

$ 14,725 Depreciation of equipment
7,218 Amortization of licensing rights
241,130 Amortization of acquired patents
$ 263,073



Interest Expense ($374,003) is comprised of interest ($268,217) based on the existing Note balance of $10,700,000 with interest accruing at 10% per annum and ($105,786) of imputed interest on the Asset Purchase Obligations, based on an interest rate of 10% per annum.





- 22 -
--------------------------------------------------------------------------------

Table of Contents



ITEM 3: CONTROLS AND PROCEDURES


Evaluation of Disclosure Controls and Procedures.


Our chief executive officer and our chief financial officer, after evaluating the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-14(c) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this quarterly report, concluded that the Company’s disclosure controls and procedures were (1) designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s chief executive officer and chief financial officer by others within those entities, particularly during the period in which this report was being prepared, and (2) effective, in that they provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.


Changes in internal controls.


There were no changes in our internal controls over financial reporting during the quarter ended March 31, 2006 that have materially affected, or are reasonably likely to material affect, our internal controls over financial reporting.




PART II: OTHER INFORMATION




ITEM 1 - LEGAL PROCEEDINGS


On June 29, 2004, a complaint was filed against the Company in the County Court, Denver County, Colorado. The complaint alleges that the Company used a telephone facsimile machine, computer or other device to send unsolicited advertisements to the facsimile machine of Cache Valley Electric without having obtained the prior express permission or invitation to do so. The plaintiff in the action seeks recovery of up to $15,000. The Company filed an answer to the complaint on July 29, 2004, and does not believe that the complaint has merit. No further action has been taken by either party as of March 31, 2006.


On January 31, 2005, a Default Judgment for $57,144 was filed against the Company in the Superior Court of Maricopa County, Arizona. The judgment was for the benefit of TGR Properties, LLC, for damages that have been incurred as a result of the premature termination of the operating lease of the facilities in Mesa, Arizona. As of April 28, 2006, the balance due on this judgment is $122,406, which includes post judgment legal fees, interest and collection costs.




ITEM 2 - UNREGISTERED SALE OF EQUITY SECURITIES


On April 18, 2006, the Company issued a certificate for 993,300 shares of common stock in payment of the commitment fee referred to in Note 10 above, for a value of $1,787,940. Such issuance was made pursuant to an exemption under Section 4(2) of the Securities Act of 1933, as amended.



- 23 -
--------------------------------------------------------------------------------

Table of Contents





ITEM 3 - DEFAULTS UPON SENIOR SECURITIES


None.




ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


On March 1, 2006 the Company filed a Definitive Schedule 14C with the Securities and Exchange Commission, a copy of which was distributed to shareholders. The Schedule 14C related to a shareholder’s meeting held on March 27, 2006 at which the shareholders approved a reverse stock split of the Company’s common stock in a ratio of 400:1, a decrease in the number of authorized shares of common stock from 400,000,000 shares to 200,000,000, the adoption of an equity incentive plan, a change of the Company’s name from “Oxford Ventures, Inc. to “ULURU Inc.” and the appointment of Kerry P. Gray, William W. Crouse, Jeffrey B. Davis and Dr. David E. Reese as the Company’s Directors.


The proposals were approved by the stockholders, as follows:


FOR AGAINST ABSTAIN
1. A proposal to authorize a reverse stock split of the Company’s common stock in a ratio of
400-for-1 was approved with: 113,705,004 -0- -0-

2. A proposal to decrease the number of authorized shares of common stock from
400,000,000 shares to 200,000,000 was approved with: 113,705,004 -0- -0-

3. A proposal to adopt the 2006 Equity Incentive Plan was approved with: 113,705,004 -0- -0-

4. Changing the Company’s name from “Oxford Ventures, Inc.” to “ULURU Inc.” was approved with: 113,705,004 -0- -0-

5. Appointment of Kerry P. Gray, William W. Crouse, Jeffrey B. Davis and Dr. David E. Reese as the Company’s Directors was approved with: 113,705,004 -0- -0-





ITEM 5: OTHER INFORMATION


None.





- 24 -
--------------------------------------------------------------------------------

Table of Contents



ITEM 6: EXHIBITS




Exhibit Number Description

31.1 Certification of Principal Executive Officer of ULURU Inc. Pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Amended

31.2 Certification of Principal Accounting Officer of ULURU Inc. Pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Amended

32.1 Certification of Chief Executive Officer of ULURU Inc. pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 Certification of Chief Financial Officer of ULURU Inc. pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

[Andreito]

hier der genaue link


http://freerealtime.brand.edgar-online.com/fetchFilingFrames…

[pedro_III]

Einfach unglaublich diese Kursentwicklung.
Gut, dass ich mich hier mit Stopp verabschieden konnte.

Eine Riesensauerei, was hier läuft

[Andreito]

du konntest dich verabschieden ich nicht, sitz erstmal im minus. mal sehen wir lange noch....

[Andreito]

man ist denn jetzt mir deal der us armee???? wird wohl nix oder wie kann ich das sehen
????

[Andreito]

hoffen wir fuer alle investierten das es schnell wieder aufwaerts geht!!!

[Andreito]

gehts doch stehen wieder ueber 1,20 dollar

[pedro_III]

Gut.
Aber: Hätte man nicht nach dem r/s für eine solide, seriöse, nachvollziehbare und vertrauensbildende Kursentwicklung sorgen müssen? Ist es denn normal, dass der Wert in den ersten Tagen nach dem split mit über 2,--$ gehandelt wurde, um dann unter 0.8 $ zu fallen? Dazu das Problem, dass der Handel seitdem in Deutschland noch immer nicht wieder aufgenommen wurde.

Ich ärgere mich über solche Auswüchse maßlos . Sie zerstören Vertrauen, denn den Wert packt vorerst keiner mehr an.

Natürlich bleibt er auf der watchlist und Dir, Andreito, der Du im Moment ziemlich allein auf weiter Flur stehst, wünsche ich viel Glück

[Andreito]

noch einer investiert???? ob die nochmehr shares auf den markt schmeissen werden???

[Andreito]

langsam gehts wieder aufwaerts.

[Andreito]

uiuiui da tut sich was oder kann mir einer den kursanstieg der letzten tagen erklaeren? wollte erst bei 1 dollar das hantuch werfen, habs aber sein gelassen und wo der kurs jetzt steht sieht ja jeder selbst. news finde ich aber keine neuen. weis einer von euch was???

[Andreito]

wird im ami land nicht mehr gehandelt???

[Andreito]

hier im thread ist ja gar nichts mehr los

seit ihr schon alle raus??? erts wurde das ding hier super schoen geredet und aufeinmal haben die leute kein interesse mehr oder was ist hier los¿?¿¿¿

[MCMLXVIII]

Damit der Thread nicht ganz eintrocknet...

Sitze auch noch auf ein paar Stücken...

News kann ich auch keine finden...

Also noch warten oder weg damit

[Andreito]

bin auch am ueberlegen ob ich verkaufen soll oder nicht... glaube aber das ich nohc etwas warten werde. was ist denn eigentlich aus dem deal mit der us amee geworden??

gruesse aus madrid

[Andreito]

man findet einfach nichts neues an news

[pedro_III]

Und heute dann minus 46% auf nur noch 0.66 $. Eine ganz peinliche Veranstaltung

[Andreito]

am ende wieder auf 1.05

weis einer wieso es auf 55 runter ging??? gab es news oder sonst etwas was den kursrutsch erklaeren kann??

[Quipu]

Wird hin und wieder mit kleinsten Stückzahlen runtergezogen.

Ich denke, es sieht schnell wieder wie im Juni aus.

[Andreito]

was ist denn los? wird hier nicht mehr gehandelt? ist das ding so uninteressant geworden???

[Andreito]

weis einer was neues? seit tagen kein handel, nicht einmal eine share

[Andreito]

Antwort auf Beitrag Nr.: 23.912.865 von Andreito am 13.09.06 17:19:14

immer noch kein handel...

weis einer von euch ob es die noch gibt??

[Andreito]

was haltet ihr davon???

Access Pharmaceuticals Announces Revised $10 Million Agreement With Uluru, Inc.
- $4.9 Million Received and Milestones of Up to an Additional $5.1 Million -
DALLAS, Dec. 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it had amended its 2005 Asset Sale Agreement with Uluru, Inc. (OTC Bulletin Board: ULUR). Access will receive from Uluru an upfront payment of $4.9 million, an additional $350,000 in 120 days plus potential milestones of up to $4.8 million based on Uluru sales. The amendment agreement included the anniversary payment due October 12, 2006, the early payment of the two year anniversary payment, and a payment in satisfaction of certain future milestones. Access also transferred to Uluru certain patent applications that Access had previously licensed to Uluru under the 2005 License Agreement. Under a new agreement, Access has acquired a license from Uluru to utilize the nanoparticle aggregate technology contained in the transferred patent applications for subcutaneous, intramuscular, intra- peritoneal and intra-tumoral drug delivery. Additionally, one future milestone has been increased by $125,000.

Access sold its oral/topical care business to Uluru, Inc. in October 2005 and to date has received a total of $13.6 million. Access may receive up to $5.1 million in future payments upon Uluru's achievement of certain sales milestones.

Rosemary Mazanet, MD, PhD, Acting CEO of Access stated, 'This payment provides the Company with the flexibility to advance the clinical development of ProLindac(TM), extend our licensing efforts with MuGard(TM) and expand our Vitamin B12 oral delivery program.'

About ProLindac(TM)

The Company's lead compound, ProLindac(TM), is a novel dach platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. The Company believes that ProLindac's unique molecular design potentially could eliminate some of the toxic neurological side effects seen in currently marketed Dach platinums. The Company is currently enrolling patients in two Phase II clinical trials, one in ovarian cancer and one in head and neck cancer, and plans to initiate one or more additional Phase II trials, including one in colorectal cancer in 2007.

About MuGard(TM)

The Company submitted a Premarket Notification 510(k) Application to the FDA announcing the Company's intent to market MuGard(TM). MuGard(TM) is Access' proprietary oral rinse product for the prevention and treatment of oral mucositis, the debilitating side-effect which afflicts more than 40% of cancer patients undergoing radiation and chemotherapy. Access is actively seeking marketing partners in Europe and the US.

About Vitamin B12

The Company is actively developing clinical development plans for its novel Vitamin B12 drug delivery technology, particularly as it pertains to the oral delivery of large molecule drugs that are only currently deliverable by injection or intravenous administration. Pre-clinical animal studies utilizing Access' VB-12 technology have demonstrated the ability to deliver insulin by oral administration in therapeutic levels. Access is actively seeking development partners in this area as well.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the treatment of patients with mucositis. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.



Source: PR Newswire (December 11, 2006 - 9:39 AM EST)

News by QuoteMedia
www.quotemedia.com

[Quipu]

Zufrieden mit der Entwicklung?

[Andreito]

ist gut, bin aber bei 1,9 dollar raus da ich dachte das es nur ein kleiner funken waere. wie es ausschaut habe ich mich geirrt naja... kann man auch nicht mehr aendern

[Sklaus]

Hallo zusammen, weiß einer warum die Aktie momentan steigt. Hatte sie schon abgeschrieben und heute zufällig im Depot die Steigerung gesehen. Gibts Neuigkeiten etc.


SKLAUS

[NewSpice]

Antwort auf Beitrag Nr.: 26.956.604 von Sklaus am 16.01.07 14:44:57

hallo zusammen bin ziehmlich neu ...kann mir einer erzählen was ULURU INC. eigentlich macht ????